JP2024502598A5 - - Google Patents

Info

Publication number
JP2024502598A5
JP2024502598A5 JP2023541536A JP2023541536A JP2024502598A5 JP 2024502598 A5 JP2024502598 A5 JP 2024502598A5 JP 2023541536 A JP2023541536 A JP 2023541536A JP 2023541536 A JP2023541536 A JP 2023541536A JP 2024502598 A5 JP2024502598 A5 JP 2024502598A5
Authority
JP
Japan
Prior art keywords
composition
ketamine
aspirin
amount
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502598A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/011630 external-priority patent/WO2022150597A1/en
Publication of JP2024502598A publication Critical patent/JP2024502598A/ja
Publication of JP2024502598A5 publication Critical patent/JP2024502598A5/ja
Pending legal-status Critical Current

Links

JP2023541536A 2021-01-08 2022-01-07 ケタミンの経口投与 Pending JP2024502598A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163135126P 2021-01-08 2021-01-08
US63/135,126 2021-01-08
US202163176654P 2021-04-19 2021-04-19
US63/176,654 2021-04-19
US202163235413P 2021-08-20 2021-08-20
US63/235,413 2021-08-20
PCT/US2022/011630 WO2022150597A1 (en) 2021-01-08 2022-01-07 Oral administration of ketamine

Publications (2)

Publication Number Publication Date
JP2024502598A JP2024502598A (ja) 2024-01-22
JP2024502598A5 true JP2024502598A5 (cg-RX-API-DMAC7.html) 2025-01-16

Family

ID=82323518

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541536A Pending JP2024502598A (ja) 2021-01-08 2022-01-07 ケタミンの経口投与

Country Status (4)

Country Link
US (2) US11382873B1 (cg-RX-API-DMAC7.html)
EP (1) EP4274557A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024502598A (cg-RX-API-DMAC7.html)
WO (1) WO2022150597A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
US20240009145A1 (en) * 2022-07-07 2024-01-11 Vitalis Analgesics LLC Compositions of aspirin and ketamine
WO2025160483A1 (en) * 2024-01-24 2025-07-31 Awakn Ls Europe Holdings Limited Oral transmucosal esketamine therapy for alcohol use disorder and substance use disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840731A (en) * 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
WO2009005803A1 (en) * 2007-07-01 2009-01-08 Joseph Peter Habboushe Combination tablet with chewable outer layer
CN107669649A (zh) * 2012-10-11 2018-02-09 Ix生物制药有限公司 固体剂型
KR20220044380A (ko) * 2013-04-12 2022-04-07 이칸 스쿨 오브 메디슨 엣 마운트 시나이 외상후 스트레스 장애의 치료 방법
US20150072005A1 (en) * 2013-09-10 2015-03-12 Vitalis Llc Aspirin formulation for increased efficacy
WO2018102488A1 (en) * 2016-11-30 2018-06-07 Wolfson Philip E Ketamine for the treatment of menstrually related symptoms
US11471415B2 (en) * 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
CN114805139B (zh) * 2018-01-10 2023-10-20 凯瑞康宁生物工程(武汉)有限公司 氯胺酮的前药、其组合物和用途
US20210308040A1 (en) * 2018-10-26 2021-10-07 Guangzhou Dazhou Biomedicine Ltd. Ketamine oral transmucosal delivery system
AU2019447630A1 (en) * 2019-05-31 2021-12-23 Celon Pharma S.A. Electronically supervised administration of a pharmaceutical composition
US20210308075A1 (en) * 2020-04-07 2021-10-07 Joseph Habboushe Prevention and treatment of virial infections

Similar Documents

Publication Publication Date Title
TWI594754B (zh) 口服皮質類固醇組合物
CA2690956C (en) Combination tablet with chewable outer layer
ES2236617T3 (es) Comprimido orodispersable que presenta una gran homogeneidad y su procedimiento de preparacion.
US8404275B2 (en) Combination tablet with chewable outer layer
WO2002060446A1 (fr) Preparation medicamenteuse contenant du 5-methyle-1-phenyle-2-(1h)-pyridone en tant que principe actif
US20060141031A1 (en) Orally disintegrating pharmaceutical compositions with sensory cue agents
BRPI0709719A2 (pt) formas de dosagem sàlida revestidas de pelÍcula
US5702723A (en) Multi-stage delivery system for ingestible medications or nutrients
KR20040058189A (ko) 관능상 허용가능한 경구내 붕해 조성물
KR20030045035A (ko) 시클로옥시게나제-2 억제제의 경구 고속-용해 제제
US20250144121A1 (en) Compositions and methods for treating multiple sclerosis
CN111065384A (zh) 扑热息痛的口腔崩解膜组合物
RU2311176C2 (ru) Амброксол для лечения болей в полости рта и глотки
US20220008331A1 (en) Pharmaceutical compositions comprising flurbiprofen
KR20140108652A (ko) 정제 및 건식-코팅된 작용제
US20060141027A1 (en) Sublingual administration of non-steroidal anti-inflammatory pharmacological substances
JP2021105057A (ja) 固形製剤
Nagpal et al. Patent innovations in fast dissolving/disintegrating dosage forms
CN1537006A (zh) 含有米尔塔扎平和对乙酰氨基酚或一种非甾类消炎药的用于治疗头痛的联合用药物
WO2024058240A1 (ja) 感冒症状軽減剤
WO2012146314A1 (en) Thin gelatin capsules for rapid drug release in the mouth
JP6855387B2 (ja) 圧縮成型製剤
US20220202722A1 (en) Orodispersible tablet
MXPA04003404A (es) Composiciones de valdecoxib de disgregacion intraoral preparadas mediante un procedimiento de desecacion por pulverizacion.
JP2005512990A (ja) 流動層造粒法により製造される口腔内崩壊型バルデコキシブ組成物